Compare iShares Core Growth Allocation ETF (AOR) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs DexCom, Inc. — how do they compare? iShares Core Growth Allocation ETF trades at $70.17, while DexCom, Inc. trades at $89.18 (market cap $33.79B). Which is the better fit depends on your goals.
| AOR | DXCM | |
|---|---|---|
52-Week High | $70.12 | $89.53 |
52-Week Low | $62.26 | $54.84 |
Market Cap | — | $33.79B |
Sector | — | Health |
Enterprise Value | — | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AOR, the iShares Core Growth Allocation ETF, trades at $69.87, showing minimal daily movement. Technical indicators are bullish based on moving averages, though the RSI suggests potential overbought conditions. The fund maintains a fixed 60/40 stock/bond allocation, offering a low-cost, diversified core holding strategy with a 20 basis point fee.
The outlook for AOR is stable, providing a straightforward asset allocation tool for long-term investors. Key risks include underperformance versus pure equity indices like the S&P 500 over extended periods, as noted by financial media, and sensitivity to interest rate changes affecting the bond portion.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
